Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on January 25, 2023, regarding events occurring on January 24, 2023. The filing details the entry into a Material Definitive Agreement for a private placement of equity securities and the creation of a new class of Series B Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial metrics relate to the proposed capital raise:
- First Tranche: Sale of 1,200,000 shares of Series B Preferred Stock at $25.00 per share (equivalent to $0.5901 per common share).
- First Tranche Proceeds: Approximately $30.0 million in gross proceeds.
- Second Tranche (Contingent): Sale of 944,160 shares at $31.77 per share (equivalent to $0.75 per common share).
- Second Tranche Proceeds: Approximately $30.0 million in gross proceeds, contingent on stock price performance.
- Total Potential Proceeds: Approximately $60.0 million.
- Use of Proceeds: General corporate purposes, including working capital, R&D, clinical trials, and potential acquisitions.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement to issue up to 2,144,160 shares of Series B Convertible Preferred Stock in two tranches. The first tranche is expected to close on January 27, 2023. The second tranche is conditional on the Company's common stock achieving a 10-day volume-weighted average price of at least $1.125 per share with aggregate trading volume of at least $25 million within 18 months of the first tranche closing.
Guidance, Risks, and Security Rights
Security Rights: The Series B Preferred Stock ranks senior to common stock and Series A preferred stock but junior to all debt obligations. It carries a liquidation preference of $1.00 per share plus unpaid dividends. Holders have voting rights on specific matters, including amendments to the Certificate of Designation or the issuance of senior stock.
Risks and Contingencies: The filing includes forward-looking statements subject to risks, including the possibility that the Private Placement may not close on the expected timing or at all. The second tranche is entirely dependent on market performance conditions that may not be met.
Key Facts for Investor Verification
- Verify the closing of the first tranche on or around January 27, 2023, and the receipt of the anticipated $30.0 million.
- Monitor the 10-day volume-weighted average price of Verastem common stock to assess the likelihood of triggering the second tranche conditions.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and limitations.
- Confirm the impact of the new Series B Preferred Stock on the existing capital structure and dilution to common shareholders upon conversion.